Furthermore, a specific mono-phosphorylated ERK2 signal, which correlated with patient response to tyrosine kinase inhibitor treatment, was identified in chronic myelogenous leukemia (CML) samples. Here, MAPK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.